Maximum quantity allowed is 999
请选择数量
CAS RN: 80214-83-1 | 產品號碼: R0164
產品規格
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 95.0 area% |
Elemental analysis(Nitrogen) | 3.10 to 3.60 % |
Specific rotation [a]20/D | -93.0 to -96.0 deg(C=1, Acetone)(calcd.on anh.substance) |
Water | max. 3.0 % |
性質
熔點 | 120 °C |
比旋光 [α]D | -95° (C=1,Acetone) |
溶解性(可溶於) | Methanol |
GHS
圖形表示 | |
信號詞 | Warning |
危險性說明 | H302 : Harmful if swallowed. |
防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
RTECS # | KF4990000 |
運輸資料
HS編碼* | 2941.90-000 |
Application
Roxithromycin: An Acid-Stable and Enteric Absorbent Semi-Synthetic Macrolide Antibiotic
Macrolide antibiotics are classified by the size of the macrocyclic lactone ring of aglycone as 14-, 15- or 16-membered ring macrolides. Macrolides are characterized by similar chemical structures, mechanisms of action and resistance, but vary in the different pharmacokinetic parameters, and spectrum of activity. Roxithromycin (abbrev: RXM) is chemically synthesized from erythromycin [E0751] to create a more acid-stable antimicrobial and prevents the degradation of the erythromycin base to the hemiketal intermediate. RXM has an in vitro antibacterial profile similar to that of erythromycin. RXM has a pharmacokinetic profile that is characterized by excellent enteric absorption within macrolide antibiotics achieving high concentrations in most tissues and body fluids. In addition, RXM immunomodulatory activities have reported.
References
- A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy
- The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin (a review)
- Roxithromycin: review of its antimicrobial activity
- Analysis of macrolide antibiotics (a review)
- Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquidchromatography with amperometric detection
- Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycin
考研文獻
文章/手冊
TCIMail
產品文件 (部分產品的分析圖譜無法提供,敬請諒解。)
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助,請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注:該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉,您搜索的分析圖譜無法提供。